My Profile
Edit Profile
My Follows
My Wires
My Drafts
Analytics
Email Preferences
Sign Out
home
most popular
Latest
Rules of Investing
Buy Hold Sell
Series
Buy Hold Sell
Expert Insights
Fund in Focus
Fund Manager Q&A
Investment Guides
Meet The Adviser
Meet The Investor
Outlook Series
Success and More Interesting Stuff
The Rules of Investing
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Contributors
Find Funds
About Livewire
Careers
Contact Us
x
Search Livewire
Search for
"
"
Write a Wire
Notifications
Loading...
Write a wire
Account
My profile
My follows
My wires
My drafts
Analytics
Email preferences
Company
About Livewire
Contact us
Sign out
Sign In
Join Free
Latest
Rules of Investing
Buy Hold Sell
Series
Buy Hold Sell
Expert Insights
Fund in Focus
Fund Manager Q&A
Investment Guides
Meet The Adviser
Meet The Investor
Outlook Series
Success and More Interesting Stuff
The Rules of Investing
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Find funds
mayne pharma
Latest news and analysis on mayne pharma
The sky is not falling, but storm clouds are brewing
The sky is not falling was the message in September 2017. Our message was that the overall market did not show excessive valuations, which generally is a precursor to...
Jason Teh
Vertium Asset Management
A new solution for doctors and painkillers
John Kimber
International Investment Research LLC
Mayne Pharma Half Year Result - MYX lifts profits on generic drug purchases and lawsuit win
CommSec
Online Stockbroker
Insight: Mayne Pharma Limited
(ASX:MYX)
Glennon Capital
ASX:GC1, ASX:CMI
Mayne Pharma Half Year Result - MYX meets expectations as Doryx delivers
CommSec
Online Stockbroker
The outlook for Healthcare stocks in
2016
Bell Potter
Stockbroker
What insights are listed company executives providing on the state of the Australian
economy
Livewire Exclusive
Livewire Markets
most
popular
Equities
Copper threatens to outshine lithium, putting leveraged juniors in the frame
Barry FitzGerald,
Independent Journalist
Equities
The ASX tech company dominating its space and why we're backing it
Tim Carleton,
Auscap Asset Management
Education
Media Worth Consuming – January 2023
Jonathan Rochford,
Narrow Road Capital
Equities
This global fund manager outperformed the market by almost 30%. Here's how they did it.
David Thornton,
Livewire Markets
view all
Sponsored
